Want to see STIM full AI Analyst Report?
STIM Stock Chart & Stats
$1.73
$0.08(4.62%)
At close: 4:00 PM EDT
$1.73
$0.08(4.62%)
Day’s Range― - ―
52-Week Range$0.80 - $4.85
Previous Close$1.8
Volume807.96K
Average Volume (3M)1.96M
Market Cap
$137.09M
Enterprise Value$170.87
Total Cash (Recent Filing)$13.21M
Total Debt (Recent Filing)$85.39M
Price to Earnings (P/E)―
Beta1.51
Next Earnings
Aug 11, 2026EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.54
Shares Outstanding69,587,840
10 Day Avg. Volume3,223,854
30 Day Avg. Volume1,959,322
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)4.07
Price to Sales (P/S)0.61
P/FCF Ratio-4.30
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$5.00Price Target Upside189.02% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.46
Revenue Forecast (FY)$161.13M
Bulls Say, Bears Say
Bulls Say
Revenue Recovery And Clinic GrowthA pronounced TTM revenue rebound indicates durable demand recovery for NeuroStar and clinic services. Higher top-line traction supports recurring consumable and service revenues, improves unit economics on installed base, and creates a structural foundation for margin stabilization and eventual free cash flow conversion if sustained.
Payer Coverage Expansion Increases Addressable MarketExpanded payer policy allowing nurse practitioners to deliver TMS materially enlarges the addressable patient population and distribution channels. This structural reimbursement change reduces adoption friction, supports higher utilization of installed systems over time and underpins a repeatable revenue stream from treatments and consumables.
Senior Finance Leadership AddedHiring an experienced CFO with a history of driving profitability and cash-flow improvements is a lasting governance and execution positive. Strengthened finance leadership can accelerate cost discipline, capital structure repair and operational initiatives, improving likelihood of meeting margin and cash-flow guidance over the medium term.
Bears Say
Ongoing Cash Burn And Low LiquidityMaterial cash depletion and a planned full‑year negative operating cash flow create persistent financing risk. Limited liquidity restricts investment in go-to-market and clinic expansion, raises dependence on external funding, and increases execution risk if revenue or margin improvements falter over the coming quarters.
Sustained Operating LossesPersistent negative operating and net margins mean the company must rely on financing or equity dilution to bridge losses. Until margins flip sustainably positive, the firm cannot rebuild retained earnings, which limits strategic optionality and makes long-term deleveraging dependent on execution and durable revenue cadence.
Elevated Leverage And Thin Equity BaseAlthough debt has been reduced, leverage remains high relative to a small equity cushion. A pressured capital structure constrains flexibility, raises refinancing vulnerability, and amplifies downside if operating performance weakens, making balance-sheet repair contingent on sustained profitability and retained earnings growth.
Neuronetics News
STIM FAQ
What was Neuronetics’s price range in the past 12 months?
Neuronetics lowest stock price was $0.80 and its highest was $4.85 in the past 12 months.
What is Neuronetics’s market cap?
Neuronetics’s market cap is $137.09M.
When is Neuronetics’s upcoming earnings report date?
Neuronetics’s upcoming earnings report date is Aug 11, 2026 which is in 9 days.
How were Neuronetics’s earnings last quarter?
Neuronetics released its earnings results on May 05, 2026. The company reported -$0.16 earnings per share for the quarter, beating the consensus estimate of -$0.174 by $0.014.
Is Neuronetics overvalued?
According to Wall Street analysts Neuronetics’s price is currently Undervalued.
Does Neuronetics pay dividends?
Neuronetics does not currently pay dividends.
What is Neuronetics’s EPS estimate?
Neuronetics’s EPS estimate is -0.12.
How many shares outstanding does Neuronetics have?
Neuronetics has 69,587,840 shares outstanding.
What happened to Neuronetics’s price movement after its last earnings report?
Neuronetics reported an EPS of -$0.16 in its last earnings report, beating expectations of -$0.174. Following the earnings report the stock price went up 7.426%.
Which hedge fund is a major shareholder of Neuronetics?
Currently, no hedge funds are holding shares in STIM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Neuronetics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.00 (189.02% Upside)
$5.00 (189.02% Upside)
Blogger Sentiment
Bullish
STIM Sentiment 67%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 56.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $753.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.9%
Last 30 Days ▲ 14.7%
Last 30 Days ▲ 14.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-61.12%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-11.65%
Trailing 12-Months
Company Description
Neuronetics
Neuronetics, Inc. functions as a medical technology enterprise with commercialized products, specializing in the creation, enhancement, and global distribution of solutions for individuals experiencing neurohealth conditions, both within the U.S. and abroad. The company's flagship product is the NeuroStar Advanced Therapy System, an in-office, non-surgical, and non-pharmaceutical treatment option available for adult patients diagnosed with major depressive disorder. This sophisticated system utilizes transcranial magnetic stimulation (TMS) to generate a pulsed magnetic field, similar in strength to an MRI, which subsequently induces electrical currents. These currents are specifically engineered to activate brain areas that are key to mood regulation. Neuronetics distributes its offerings directly to psychiatrists through its dedicated sales and client support personnel. Established in 2001, the company's corporate headquarters are situated in Malvern, Pennsylvania.
STIM Company Deck
STIM Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a mixed but constructive view: top-line growth (total revenue +8%, clinic revenue +15%), improved profitability trends (narrower net loss and $2.0M adjusted EBITDA improvement), and meaningful operational initiatives (cost savings, go-to-market pilots, payer/regulatory tailwinds). Offsetting these positives are ongoing challenges including NeuroStar treatment revenue declines, gross margin contraction, a materially reduced cash balance ($19.0M vs $34.1M at year-end), continued GAAP losses and a near-term projected operating cash burn for the year. Management emphasized discipline, cash-flow focus, and pilots to expand reach — signaling a path to stabilization but with execution and liquidity risks to manage in the near term.View all STIM earnings summariesSTIM Stock 12 Month Forecast
Average Price Target
$5.00
▲(189.02% Upside)
Technical Analysis
Ownership Overview
31.16% Insiders
5.57% Mutual Funds
0.10% Other Institutional Investors
59.55% Public Companies and
Individual Investors